Preresection Chemotherapy Improves Survival for Children With Askin Tumors

Abstract

Patients with Askin tumor treated with aggressive preresection chemotherapy have smaller tumors to resect and improved survival.

Noninvasive ventilation in large postoperative flail chest

“…An aggressive multimodal approach (chemotherapy, surgery, and radiotherapy) is the common treatment. Some data seem to justify the use of chemotherapy in a preoperative setting to achieve a safer and easier surgery 4, 5. Preoperative chemotherapy also allows to obtain informations about tumor chemosensitivity 4, 5.…”

Locally Advanced Askin’s Tumour in a Child—a Rare Case Report and Review of the Literature

“…In view of post-operative negative margins, radiotherapy was not given in the index case. Sawin et al demonstrated that pre-operative chemotherapy resulted not only in a reduced tumor volume, but also in prolonged survival rates [8]. Veronesi et al summarized the benefits of pre-operative chemotherapy, including the reduction in the risk of intraoperative tumor rupture and tumor cell dissemination, the increase in the probability of R0 resection, the enhanced probability of post-operative function preservation by a more conservative surgical approach, the decrease in any occult distant spread and the provision of a pathological and clinical evaluation of the response that favors the choice of the best post-operative regimen of chemotherapy and radiotherapy [9].…”

“…The prognosis of Askin's tumor is very poor as it is diagnosed at an advanced stage and the 5 year survival rates ranges from 10 to 60 % [3,4,8,10]. The best prognosis can be provided by surgical treatment with wide resection.…”

Treatment of an Askin tumor: A case report and review of the literature

“…In certain cases, extended surgery followed by post-operative chemotherapy and radiotherapy is the first choice of treatment (31). A number of researchers have reported the potential advantages of pre-operative chemotherapy with reference to the treatment of Ewing sarcoma (32,33). Veronesi et al (32) summarized the benefits of pre-operative chemotherapy, including the reduction in the risk of intraoperative tumor rupture and tumor cell dissemination, the increase in the probability of R0 resection, the enhanced probability of post-operative function preservation by a more conservative surgical approach, the decrease in any occult distant spread and the provision of a pathological and clinical evaluation of the response that favors the choice of the best post-operative regimen of chemotherapy and radiotherapy.…”

“…Veronesi et al (32) summarized the benefits of pre-operative chemotherapy, including the reduction in the risk of intraoperative tumor rupture and tumor cell dissemination, the increase in the probability of R0 resection, the enhanced probability of post-operative function preservation by a more conservative surgical approach, the decrease in any occult distant spread and the provision of a pathological and clinical evaluation of the response that favors the choice of the best post-operative regimen of chemotherapy and radiotherapy. Sawin et al (33) demonstrated that pre-operative chemotherapy resulted not only in a reduced tumor volume (from 7,054 to 911 cm 3 ), but also in prolonged survival rates. Demir et al (18) reported that neoadjuvant chemotherapy significantly increased the complete resection rate (P=0.027) and that the 5-year survival rates of the patients with or without neoadjuvant therapy were 77 and 37%, respectively (P=0.22).…”